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Abstract
Background: The integrase strand transfer inhibitor dolutegravir (DTG) is being introduced into low- and middle-income
countries (LMICs) as an alternative to first-line treatment with non-nucleoside reverse transcriptase inhibitors. However,
DTG is not yet widely recommended for use in pregnant women. The aim of this systematic review was to analyse all
available data on birth outcomes and congenital anomalies in the infants of pregnant women treated with DTG.
Methods: A PubMed and Embase search was conducted using the terms “dolutegravir” or “DTG” and “pregnancy” or
“pregnant” from the earliest available date on the database to 26 July 2017. Any reports involving women who were
pregnant, HIV positive and taking DTG were included. The percentage of pregnant women with adverse birth outcomes
or congenital anomalies in their infants after taking dolutegravir was compared with five historical control databases.
Results: There were six databases included in the main analysis of birth outcomes and congenital anomalies, with a total
of 1200 pregnant women. The percentage of pregnant women taking DTG with adverse birth outcomes and congenital
abnormalities was similar to results from historical control studies of HIV-positive women. However, there was significant
heterogeneity among the six databases – the percentage of infants with congenital anomalies ranged from 0.0% in Botswana
(0/116 infants) to 13.3% in IMPAACT P1026S (2/15 infants).
Conclusions: Up to 15 million people could be on treatment with DTG in LMICs within the next 5 years, of whom a
substantial percentage is likely to be women of child-bearing potential. In many countries with large HIV epidemics, unplanned
pregnancies are common and access to antenatal clinic facilities may be limited. Continued pharmacovigilance is essential,
but it is reassuring that no clear safety signals have been detected, to date, for pregnant women treated with DTG in
terms of birth outcomes or congenital anomalies.
Introduction
The integrase strand transfer inhibitor (INSTI) dolutegravir (DTG)
is recommended as an alternative first-line HIV treatment to
efavirenz (EFV) in the current World Health Organization (WHO)
consolidated antiretroviral (ARV) guidelines [1], and is widely
recommended in other international treatment guidelines [2–4].
The efficacy of DTG has been established in studies of naive and
pre-treated patients [5–8]. In particular, DTG has shown an
improved safety profile compared to the non-nucleoside reverse
transcriptase inhibitor (NNRTI) EFV as first-line treatment [5].
Generic versions of DTG have already become available as a single
tablet regimen [9]. A generic fixed-dose combination of tenofovir,
lamivudine and dolutegravir (TDF/3TC/DTG) is now becoming
available in some low- and middle-income countries (LMICs) at
a median price of US$75 per person-year, making a DTG-
containing regimen more affordable than first-line EFV-containing
regimens [10].
As of November 2017, almost 60 LMICs have adopted or are
planning to incorporate DTG into national treatment guidelines.
Brazil, Botswana, Kenya and Uganda have already started treating
patients with DTG [11]. The President‘s Emergency Programme
on AIDS Research (PEPFAR) has recommended the rapid
introduction of DTG in its key target countries. It has been estimated
that approximately 15 million people will be taking DTG by 2025
and that it will replace first-line EFV-based regimens [9,11].
The risks of adverse birth outcomes with in utero exposure to
DTG should be evaluated before widespread introduction of
DTG into national treatment programmes in LMICs, where women
of childbearing age represent a large proportion of the HIV-positive
population. Animal studies of DTG on rats and rabbits revealed
an absence of infertility or harm to the fetus, even at high
doses [12,13]. There is evidence from ex vivo animal studies
that DTG penetrates the placenta [14], and as has been reported
for other INSTIs, two case reports of infants exposed to DTG
in utero have demonstrated cord blood drug concentrations
higher than maternal plasma concentrations, suggesting signifi-
cant fetal exposure [15]. Furthermore, the plasma half-life of
DTG has been estimated to be twice as long in neonates as in
adults [16,17]. DTG has also been shown to transfer into
breast milk, resulting in significant plasma concentrations in the
infant [18].
Randomised clinical trials assessing DTG in pregnancy, compared
with other antiretrovirals, are in progress, but results will not be
available until 2019–2020 [11]. Notably, in utero exposure to the
first in-class INSTI raltegravir (RAL) has not been associated with
birth defects, based on a substantial number of reported exposures
to date (over 400 first trimester exposures have been reported
to the Antiretroviral Pregnancy Registry [19] and nearly 500
exposures in the French Perinatal Cohort, of which 42% were in
the first trimester [20]).
DTG is indicated for use in pregnancy when the benefits outweigh
the risks [12]. The WHO currently lists DTG as an alternative, rather
than a preferred option, for first-line HIV treatment, partly due
to the limited safety and effectiveness data available in pregnant
women [1]. In October 2017, the US Department of Health and
Human Services (DHHS) guidelines noted that there was sufficient
data to recommend routine use of DTG-containing regimens for
antiretroviral-naive pregnant women as an alternative agent for
antiretroviral-naive women [19].
*Correspondence author: Dr Andrew M Hill, Department of Translational
Medicine, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF,
UK.
Email: microhaart@aol.com
Journal of Virus Eradication 2018; 4: 66–71ORIGINAL RESEARCH
© 2018 The Authors. Journal of Virus Eradication published by Mediscript Ltd
This is an open access article published under the terms of a Creative Commons License.66
Botswana is currently the only LMIC where DTG is being widely
used in pregnant women [11]. There is an ongoing research project
in Botswana to assess birth outcomes and congenital anomalies
in the infants of pregnant women treated with DTG, as part of a
wider research programme to assess the safety of antiretrovirals
in pregnancy [21]. In North America and Europe, where women
take DTG during pregnancy, there are observational studies and
research projects under way to evaluate birth outcomes, congenital
anomalies and pharmacokinetics.
This systematic review was conducted to assess the prevalence
of specific pregnancy outcomes and birth defects, and
pharmacokinetics for pregnant women living with HIV who are
taking DTG.
Methods
For this systematic review, a PubMed and Embase search was
conducted using the terms “dolutegravir” or “DTG” and
“pregnancy” or “pregnant” from the earliest available date on the
database to 26 July 2017. This was cross referenced with a search
of the clinical trials database, www.clinicaltrials.gov, and conference
abstracts from the International AIDS Society (IAS) Conference
in July 2017.
During the original clinical trials programme for DTG, women were
advised to use contraception, and any women who became
pregnant were discontinued from treatment with DTG. These
measures, although typical for early clinical development studies,
have resulted in a paucity of data regarding treatment outcome
in pregnant women. Therefore, since randomised trials have not
yet been completed, the main source of information on DTG in
pregnancy is from non-randomised observational studies.
Any reports or databases involving women who were pregnant,
living with HIV and taking DTG were included. In case of duplicate
reports from the same research group, the most recent publication
was used. Studies were excluded if their data had been reported
in other larger research programmes, or if the number of pregnant
women treated was less than five (Figure 1).
In terms of the eligible databases, participant baseline
characteristics collected included ethnicity and trimester of
exposure. Effectiveness was defined as the number of children
with an HIV-1 negative status. Pharmacokinetic information was
identified from: drug cord blood to maternal plasma ratio; area
under the curve geometric mean; and Cmin in the third trimester.
Pregnancy outcomes included mean birth weight, stillbirth, preterm
birth (<37 weeks) and small for gestational age (SGA) (<10th
percentile). Birth defect information was collected on any
congenital abnormality or anomaly reported in a trial, study or
case report meeting eligibility criteria.
Data analysis
The main analysis concentrated on birth outcomes and congenital
anomalies. This analysis included the six largest databases, shown
in Table 1. The prevalence of birth outcomes and congenital
anomalies was compared to prevalence seen globally and in five
historical control studies of pregnant women living with HIV
[22–26]. Pharmacokinetic data were recorded where evaluated.
67 articles identified through EMBASE
and 23 through PubMed
6 duplicates
removed
84 database records screened
10 full text articles assessed, eligibility
74 trials excluded
37 Intervention not DTG
28 Study did not contain data on
DTG in pregnant women
9 Population was not pregnant
women
2 trials excluded
1 Intervention was not DTG
1 study was not in pregnant women
8 articles eligible 
1 abstract and 2 posters from IAS
2017 conference added.
1 trial was added from
clinicaltrials.gov website
6/12 articles included for analysis
(4 duplicate studies, 2 studies <5
women)
Figure 1. Outcome of the systematic review.
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Results
Literature search
The search identified 23 published articles from PubMed and 67
conference presentations from Embase. From this set, eight
contained data on DTG in pregnancy (shown in Table 1). Three
further abstracts were then added from the International AIDS
Society Conference in Paris, July 2017, and one additional study
was identified from the clinical trials registry www.clinicaltrials.gov.
It led to a total of 12 articles or conference presentations for
analysis [27–36]. Of these, two were pharmacokinetic studies, three
were prospective cohort studies, five were case reports, one was
the Antiretroviral Pregnancy Registry (APR) and one was pregnancy
outcome data from the pharmaceutical company ViiV, which
developed DTG. Six of these articles were then excluded: two
studies were already reported in the EPPIIC study [33,34]; two
were already reported in the Antiretroviral Pregnancy Registry
[15,17]; and two (one in four mothers [35], one for a single mother
[36]) were too small for inclusion (Figure 1).
There were six studies that were included in the main analysis of
birth outcomes and congenital anomalies, with a total of 1200
pregnant women:
1. Botswana [27]
This ongoing prospective cohort study in Botswana consisted of
845 women initiating treatment with DTG during pregnancy and
4593 women initiating treatment with EFV during pregnancy.
Adverse pregnancy outcomes recorded were: stillbirth, preterm
birth (<37 weeks), very preterm birth (<32 weeks), SGA (<10th
percentile), very SGA (<3rd percentile) and neonatal death.
Congenital anomalies were assessed in both live and stillbirths by
nurse surface exam at the time of birth, photographed (with
maternal consent) and reviewed by a medical geneticist, for 116
mothers taking DTG in the first trimester.
2. Antiretroviral Pregnancy Registry (APR) [28]
The APR is a voluntary reporting system that includes outcomes
for only a minority of births at the national level and does not
contain the outcomes of all births with first-trimester exposure
to DTG. The APR data consisted of 142 women (140 HIV positive,
two HIV negative) reported to be taking DTG during pregnancy.
Of these, 88 women were exposed to DTG in the first trimester
and 54 in the second or third trimesters. The women were mainly
from treatment centres in the USA (92%). Data were collected
prospectively. Adverse pregnancy outcome measures included
stillbirths, spontaneous abortions, SGA and low birthweight.
Congenital anomalies were reported from only the live births in
this cohort. In the APR, results from individual drugs are normally
compared with other drugs after outcomes are available for at least
200 mothers. This threshold has not yet been reached, but current
results are shown in Table 2, compared to other reference cohorts.
3. EPPICC, PANNA and NEAT-ID [29]
The study includes 101 pregnancies from seven countries in
Europe. It has included data collected from the European
Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC),
NEAT-ID network and PANNA (Pharmacokinetics of newly
developed ANtiretroviral agents in HIV-infected pregNAnt women).
All sources of data were collected prospectively. Adverse pregnancy
outcomes collected included stillbirth, spontaneous abortion, SGA
and low birthweight. Congenital anomaly data were available for
81 of the 84 live births [28].
Within this set of studies, PANNA [30] included analysis of
pharmacokinetics of DTG during the third trimester and
postpartum.
4. DTG Phase 3 trials [11, 31]
This database includes adverse events reported in ViiV-sponsored
Phase 2 and Phase 3 trials of DTG, either using a 50-mg tablet
or in combination with abacavir and lamivudine. This database
included information on congenital anomalies. Pregnancy was an
exclusion criterion for most of these clinical trials. However, women
who became pregnant after starting randomly allocated treatment
were then followed up to monitor the pregnancy outcome.
5. DTG post-marketing surveillance [11,31]
This database includes reports of congenital anomalies and birth
outcomes sent from clinicians to ViiV, for patients taking DTG in
pregnancy. This reporting of pregnancy outcomes is not mandated
by the originator company.
6. IMPAACT P1026s [32]
IMPAACT P1026s is an ongoing, non-randomised, parallel group
pharmacokinetic study evaluating ARVs in pregnancy. In this study,
15 women were taking DTG. In addition, pregnancy outcomes and
birth defects were evaluated by the investigators.
Pharmacokinetics of DTG in pregnancy
In the IMPAACT P1026S study, DTG area under the curve (AUC)
exposures were 25–30% lower in the second or third trimesters,
compared to postpartum [32]. In the PANNA study, DTG AUC
exposures were a median 50% lower in the third trimester of
Table 1. Studies included in the systematic review
Study [ref] Study design n Location Trimester
exposure
Included studies
BOTSWANA [26] Cohort study 845 Africa 2nd (median)
APR [27] Prospective report 142 North America, Europe, South
America and Australia
1st: 88
2nd–3rd: 54
EPPICC+PANNA+NEAT-ID [29,30] Pooled analysis of prospective
observational studies
101 Europe 1st: 58
2nd: 21
3rd: 18
DTG post-marketing surveillance [11,31] ViiV safety database 67 International No data
DTG Phase 3 trials [11,31] ViiV safety database 30 International No data
IMPAACT P1026s [32] Pharmacokinetic study 15 US 2nd and 3rd
aReported with EPPICC; bReported in APR
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pregnancy, compared with postpartum. However, DTG Cmin levels
remained above minimum effective concentrations. The median
DTG exposures in cord blood were 40% higher than in maternal
blood, suggesting that DTG crosses the placenta efficiently [30].
Three studies reported the cord blood to maternal plasma ratio
with a mean of 1.33 [30].
Pregnancy outcomes
There were no reports of vertical HIV transmission in any of the
studies, but data were only available for 42 infants in four studies
at the time of the analyses.
The data from Botswana (Table 3) are reported separately due
to it being the only study with a control group. The study found
no significant difference in birth outcomes between DTG and EFV,
in multivariate analysis adjusted for maternal age, gravidity and
education.
Table 2 displays the pregnancy outcomes for the six studies
included in the main analysis, compared with results from
comparator control studies in HIV-positive pregnant women in a
range of countries. There were no clear differences in the risk of
stillbirth, preterm birth (<37 weeks) or SGA between the studies
of DTG-treated women and the historical control studies.
Congenital anomalies
For the six main studies, there were 442 live births with information
available on congenital anomalies (Table 4). There were 16 infants
with congenital anomalies reported. The most common anomaly
in the babies born to mothers who took DTG
was polydactyly, with five cases. Polydactyly
is also a very common anomaly in babies
unexposed to HIV, seen in more than 1% of
births to women of African descent [37]. In
some of the studies, polydactyly was classified
as a normal variant and not included in the
final results (for example in the IMPAACT
P1026s study).
The percentage of infants with congenital
anomalies varied between the studies, ranging
from 0/116 infants in the Botswana study
(0%) to 2/15 infants in the IMPAACT P1026S
study (13.3%) (Table 4). In IMPAACT P1026S,
five of the 15 DTG-exposed babies were reported to have
congenital anomalies; there were two other babies whose
anomalies were judged to be ‘normal variants’. The investigators
judged that, based on the nature of the anomalies and the timing
of first exposure in pregnancy, the association of DTG with these
anomalies could be ruled out for all but two of the anomalies (renal
cysts, shown in Table 4). Owing to the gestational age at which
DTG was started and the nature of the renal cysts, the investigators
also considered it unlikely that these were related to exposure to
DTG. There was no clear pattern of specific congenital anomalies
recorded across all the studies. Detailed evaluation of the potential
causality for these anomalies would require more information on
the timing of initiation of DTG in each pregnant mother – this
information is not available for all studies in the systematic review.
Discussion
This systematic review of DTG use in HIV-positive pregnant women
shows no evidence for increased risks of stillbirth, preterm birth,
SGA or congenital anomalies, compared to historical control studies
of ARV-treated pregnant women. The largest observational study
in Botswana shows no evidence for increased risk of adverse birth
outcomes for women treated with DTG compared with EFV, which
has shown a favourable safety profile in a recent analysis [27].
There were no cases of perinatal transmission of HIV reported.
Pharmacokinetic studies show lower DTG exposures during the
third trimester of pregnancy compared to postpartum. However,
this pharmacological effect has also been seen for other
antiretrovirals, and all women evaluated maintained DTG exposures
Table 2. Prevalence of pregnancy outcomes and birth defects in mothers taking ARVs, from six studies of dolutegravir and four control databases
Trial location and year [ref] n Congenital
anomalies (%)
Still
birth (%)
Preterm birth
<37 weeks (%)
Small for
gestational age (%)
Control databases
France 2017 [22] 13,272 4.4 0.7 14.0
Botswana 2012 [23] 9504 2.3 4.6 23.7 18.4
SA/Zambia 2014 [24] 600 6.2 2.0 24.0 –
Zambia 2012 [25] 1229 – 2.6 16.3 –
UK 2017 [26] 6073 2.9 - 10.4 –
DTG studies [ref]
APR [28] 142 3.0 0.0 10.9 11.8
EPPICC/NEAT/PANNA [30] 81 4.9 1.0 13.9 18.7
Botswana [27] 845 0.0% 2.1 17.8 18.7
DTG post-marketing surveillance [11,31] 67 7.5 – – –
DTG Phase 3 trials [11,31] 30 3.3 – – –
IMPAACT
P1026S [32]
15 13.3 – – –
Table 3. Pregnancy outcomes from the Botswana cohort
Botswana DTG/TDF/FTC
(n=845)
EFV/TDF/FTC
(n=4593)
Stillbirth 18 2.1% 105 2.3%
Neonatal death 11 1.3% 60 1.3%
Preterm birth (<37 weeks) 149 17.6% 844 18.4%
Preterm birth (<32 weeks) 35 4.1% 160 3.5%
Small for gestational age (<10th percentile) 156 18.5% 838 18.3%
Small for gestational age (<3rd percentile) 51 6.0% 302 6.6%
Congenital anomalies 0/116 0.0% 1/396 0.3%
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above minimum effective levels. In addition, there was evidence
for transplacental passage – median DTG concentrations were 40%
higher in cord blood compared to maternal blood.
There are several limitations to this systematic review. Two
databases of publications or conference presentations in English
were searched – there may be additional reports in other
languages. There were only six publications identified, including
1200 women, with data on outcomes from 442 live births.
Publications with clear evidence for duplicate reporting were
excluded. However, it is possible that data from the studies
included in the main analysis could have been reported in the APR
as well. We believe that this was unlikely, given that 92% of women
in the current APR were from the USA,
whereas the other five studies in this review
were enrolled outside the USA.
None of the studies included was a
randomised clinical trial evaluating outcomes
for mothers taking DTG versus other
antiretrovirals. Several randomised trials of
DTG have been conducted over the past 5
years, but pregnant women have been
excluded and so outcome data are not yet
available. There are four ongoing randomised
trials of DTG in pregnancy (Table 5). Three
of these include a control arm of EFV, while
one includes atazanavir/ritonavir. DOLPHIN-1
is a randomised comparison of TDF/FTC plus
either DTG or EFV given in the third trimester
of pregnancy in Uganda, in 60 women. This
study has been fully recruited and final results
are expected in mid-2018. There is a follow
up study – DOLPHIN-2 – with a similar
design but a larger sample size of 250
women. This study is currently recruiting. The
VESTED study includes three arms: TAF/FTC/
DTG, TDF/FTC/DTG and TDF/FTC/EFV in
550 pregnant women. This trial is also
recruiting, with initial results expected in
mid-2019. Before the combined results of the
DOLPHIN and VESTED studies become
available, it will be necessary to make clinical
decisions about the safety and efficacy of
DTG in pregnancy from non-randomised
studies, which could be prone to bias.
Data from non-randomised trials have been
used widely in the assessment of safety of
ARVs in pregnancy. There are potential biases
with this approach. For example, if the
collection or reporting of results is not
prospective, there is the potential for over-
reporting of adverse outcomes. Reports sent
to the originator company, ViiV, as part of
post-marketing surveillance is voluntary and
may not represent a random sample of
treated pregnant mothers with DTG and may
not provide an accurate picture of the safety
profile of DTG in pregnancy. Other studies
where pregnant women are enrolled into trials
and studied systematically and prospectively
(such as in Botswana) are less prone to this
reporting bias. In the Botswana study, the
nurse examination of the infant after birth
might miss congenital anomalies; longer-term
follow-up would be beneficial.
The most standardised mechanism for evaluating the safety of
antiretrovirals in pregnancy has been by analysis of the APR, after
data has been collected from at least 200 mothers treated with
the antiretroviral under investigation during the first trimester. DTG
is not yet at this stage of evaluation, with only 88 women exposed
in the first trimester (71 live births), by the most recent analysis
in January 2017. The speed of introduction of DTG in LMICs has
necessitated a review of safety before mature results become
available from the APR. Therefore our analysis should be repeated
in 6–12 months, when more results become available.
The studies included in this systematic review have used a range
of methods to ascertain and define congenital anomalies. In the
Table 4. Congenital anomalies reported for infants born from DTG-treated mothers
Studies [ref] Congenital
anomalies
(N)
Percentage (%)
(95% confidence
interval)
Botswana [27]
No major anomalies reported 0/116 0% (0.0–3.1%)
APR [28]
Polydactyly 2/133
Hypoglossia 1/133
Down‘s syndrome 1/133
Total 4/133 3.0% (0.8–7.5%)
EPPICC+PANNA+NEAT-ID [29]
Patent foramen ovale 1/81
Bilateral hexadactyly hands (polydactyly) 1/81
Hypospadias
Ankyloglossia 1/81
Hyperpigmentation 1/81
Total 4/81 4.9% (1.4–12.2%)
DTG post-marketing surveillance [31]
Polydactyly 3/67
Intracranial calcifications and growth retardation 1/67
Bilateral hydroureter, hydronephrosis and
pyelocaliectasis
1/67
Total 5/67 7.5% (2.5–16.6%)
DTG Phase 3 trials [31]
Ventricular septal defect 1/30 3.3% (0.1–17.2%)
IMPAACT P1026s [32]
Multicystic dysplastic right kidney 1/15
Cyst in left kidney 1/15
Total 2/15 13.3% (1.7–40.5%)
Table 5. Ongoing randomised clinical trials of DTG in pregnant women [11]
Clinical
trial
Treatment arms Sample
size
Inclusion Time expected
first results
DOLPHIN-1 TDF/FTC/EFV 600
TDF/FTC/DTG
60 Pregnant women
Uganda, South Africa
2Q2018
DOLPHIN-2 TDF/3TC/EFV 600
TDF/3TC/DTG
250 Pregnant women
Uganda, South Africa
2Q2019
VESTED TDF/FTC/EFV 600
TDF/FTC/DTG
TAF/FTC/DTG
550 Pregnant women
International
2Q2019
ING20026 TDF/FTC/ATV/r
TDF/FTC/DTG
25 Pregnant women
International
Sub-study of ARIA
2020
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Botswana study, the method was based on visual inspection of
babies just after birth and only major congenital anomalies were
reported (defined as having clinical, surgical or cosmetic
significance) with no major congenital anomalies detected among
the 116 babies born to mothers treated with DTG in the first
trimester. The other studies included in the review had longer
follow-up of the babies and were able to use imaging and genetic
testing to evaluate birth defects. However, these studies reported
all anomalies, including some that would not normally be classified
as birth defects and some that occur among women without
first-trimester exposure to DTG. This may have resulted in higher
estimates of anomaly rates, for example in the IMPAACT P1026s
study, where there were two anomalies detected among 15 births
(13.3%). Some of the estimates presented are also limited by the
small denominators, with a single additional anomaly potentially
resulting in a large percentage difference. Although methodologies
differ between these studies included in this review, there were
no common severe malformations or a pattern of multiple
malformations seen in more than 400 births.
Up to 15 million people could be on treatment with DTG in LMICs
within the next 5 years [9,11], and among these a substantial
percentage are likely to be women of child-bearing potential. In
many countries with large HIV epidemics, unplanned pregnancies
are common and access to antenatal clinic facilities may be limited.
Given these issues, continued pharmacovigilance is essential.
However, it is reassuring that no clear safety signals have been
detected, to date, for pregnant women treated with DTG in terms
of birth outcomes or congenital anomalies.
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